Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor: Kivu Bioscience Inc.
Summary
This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Official title: A Phase 1 Dose-Finding and Dose Optimization-Expansion Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2026-06
Completion Date
2029-12
Last Updated
2026-07-10
Healthy Volunteers
No
Conditions
Interventions
KIVU-305
KIVU-305 will be administered IV .
Locations (3)
Kivu Trial Site
Sydney, New South Wales, Australia
Kivu Trial Site
Wollongong, New South Wales, Australia
Kivu Trial Site
Brisbane, Queensland, Australia